GlassScriptPhysician profile
David S Clifford
NPI 1386604775
$8,449.45
in general payments reported to CMS, 2019-2025
46 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $924 · 2021: $1,517 · 2022: $1,269 · 2023: $1,500 · 2024: $1,151 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,656 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,655.96 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,157.60 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $739.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $505.93 | 2019-2024 | Vraylar, Linzess, Creon |
| Pfizer INC. | $476.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $410.11 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $385.18 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $340.87 | 2019-2023 | |
| Astellas Pharma US INC | $337.15 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $327.28 | 2019-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Amgen INC. | $297.27 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $271.92 | 2020-2025 | Jardiance, Zepbound, Emgality |
| Janssen Pharmaceuticals, INC | $205.68 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.07 | 2019-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $168.08 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.00 | 2021-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Clifford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.